|
시장보고서
상품코드
1983134
그레이브스병 시장 : 질환 유형별, 증상별, 진단법별, 치료법별, 최종사용자별, 유통 채널별, 지역별Graves Disease Market, By Disease Type, By Symptom, By Diagnostic Method, By Treatment Modality, By End User, By Distribution Channel, By Geography |
||||||
그레이브스병 시장은 2026년에 23억 달러로 추정되며, 2033년까지 32억 6,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 5.1%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 23억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 5.10% | 2033년 시장 규모 예측: | 32억 6,000만 달러 |
갑상선 질환은 갑상선 자극 면역글로불린(TSI) 항체에 의해 갑상선이 과도하게 자극되어 갑상선 기능 항진증을 유발하는 것이 특징인 갑상선 질환은 세계 자가면역질환 시장에서 중요한 부문입니다. 이 자가면역질환은 전 세계 인구의 약 1-2%가 앓고 있으며, 여성은 남성에 비해 5-10배 더 발병하기 쉽고, 보통 30-50세에 발병합니다.
세계 갑상선 질환 시장에는 항갑상선제(메티마졸, 프로피르티오우라실), 방사성 요오드 요법, 증상 조절을 위한 베타 차단제, 갑상선 절제술 등 다양한 치료법이 있습니다. 이 시장은 갑상선 질환의 유병률 증가, 첨단 갑상선 기능 검사 및 영상 진단 기술을 통한 진단 능력 향상, 자가면역성 갑상선 질환에 대한 인식 증가에 힘입어 성장하고 있습니다.
이 질환은 만성적인 성격을 띠고 빈맥, 체중 감소, 불안, 안질환 등의 증상을 통해 환자의 삶의 질에 심각한 영향을 미치기 때문에 전 세계 의료 시스템에서 효과적인 치료법에 대한 요구가 증가하고 있습니다. 새로운 치료법을 개발하는 제약회사, 진단 기기 제조업체, 종합적인 치료 프로토콜을 제공하는 의료 서비스 제공자 등 다양한 시장 기업들이 바세도우병은 광범위한 내분비학 및 면역학 치료 영역에서 큰 시장 기회로 자리매김하고 있습니다.
시장 역학
세계 그레이브스병 시장은 시장 확대와 치료법 발전을 종합적으로 촉진하는 몇 가지 주요 촉진요인에 의해 주도되고 있습니다. 주요 촉진요인으로는 전 세계 자가면역질환의 유병률 증가를 들 수 있습니다. 환경적 요인, 유전적 소인, 생활습관의 변화가 다양한 인구 집단에서 갑상선 질환의 발병률 증가에 기여하고 있습니다. TSI 항체 검출, 갑상선 초음파 검사, 방사성 요오드 흡수 검사 등 첨단 갑상선 기능 검사를 통한 진단 능력의 향상으로 질병을 조기에 발견하고 적절한 치료를 시작할 수 있게 되어, 치료 개입을 원하는 환자군을 확대하고 있습니다.
의료비 증가, 만성 자가면역질환에 대한 보험 적용 범위 확대, 디지털 건강 플랫폼과 환자 지원 단체를 통한 환자 인식 개선은 시장 수요를 크게 증가시키고 있습니다. 그러나 시장에는 장기 복용에 따른 높은 치료비, 항갑상선제의 잠재적 부작용으로 인한 치료 중단, 신흥 시장에서의 전문 내분비내과 전문의 부족 등의 제약요인이 존재합니다. 방사성 요오드 요법을 둘러싼 규제의 복잡성, 지역별 치료 가이드라인의 차이, 환자 개개인의 차이로 인한 최적의 치료 결과 달성의 어려움은 추가적인 시장 장벽으로 작용하고 있습니다.
이러한 제약에도 불구하고, 단클론항체, 면역조절제, 유전자 프로파일링에 기반한 맞춤형 의료 접근법 등 새로운 치료법 개발을 통해 큰 기회가 창출되고 있습니다. 원격 환자 모니터링을 위한 원격의료 플랫폼, 인공지능을 활용한 진단 도구, 환자 중심 케어 모델의 통합은 큰 성장 기회를 가져다 줄 것입니다. 또한, 신흥국의 의료 인프라 확충, 자가면역질환 치료제에 대한 연구 투자 증가, 병용요법에 대한 관심 증가는 시장 진입 기업들에게 미충족 수요를 활용하고 전 세계 그레이브스병 환자들의 치료 결과를 개선할 수 있는 유망한 경로를 제공하고 있습니다.
본 조사의 주요 특징
- 세계의 그레이브스병 시장에 대해 조사 분석했으며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모(10억 달러)와 CAGR(연평균 성장률)을 예측한 보고서입니다.
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하고 있는 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계 그레이브스병 시장의 주요 업체를 프로파일링합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 그레이브스병 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 그레이브스병 시장 : 질환 유형별, 2021-2033년
제5장 세계의 그레이브스병 시장 : 증상별, 2021-2033년
제6장 세계의 그레이브스병 시장 : 진단법별, 2021-2033년
제7장 세계의 그레이브스병 시장 : 치료법별, 2021-2033년
제8장 세계의 그레이브스병 시장 : 최종사용자별, 2021-2033년
제9장 세계의 그레이브스병 시장 : 유통 채널별, 2021-2033년
제10장 세계의 그레이브스병 시장 : 지역별, 2021-2033년
제11장 경쟁 구도
제12장 애널리스트의 추천
제13장 참고문헌 및 조사 방법
KSM 26.04.15Graves' Disease Market is estimated to be valued at USD 2.30 Bn in 2026 and is expected to reach USD 3.26 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.30 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.10% | 2033 Value Projection: | USD 3.26 Bn |
Graves' disease represents a critical segment within the global autoimmune disorders market, characterized by hyperthyroidism caused by thyroid-stimulating immunoglobulin (TSI) antibodies that overstimulate the thyroid gland. This autoimmune condition affects approximately 1-2% of the global population, with women being five to ten times more likely to develop the disease than men, typically manifesting between ages 30-50.
The global graves' disease market encompasses various therapeutic interventions including antithyroid medications (methimazole, propylthiouracil), radioactive iodine therapy, beta-blockers for symptom management, and surgical thyroidectomy procedures. The market is driven by increasing prevalence rates, enhanced diagnostic capabilities through advanced thyroid function tests and imaging technologies, and growing awareness about autoimmune thyroid disorders.
Healthcare systems worldwide are witnessing rising demand for effective treatment modalities due to the chronic nature of the condition and its significant impact on patients' quality of life, including symptoms such as rapid heartbeat, weight loss, anxiety, and ophthalmopathy. The market landscape includes pharmaceutical companies developing novel therapeutic approaches, diagnostic equipment manufacturers, and healthcare service providers offering comprehensive treatment protocols, positioning graves' disease as a substantial market opportunity within the broader endocrinology and immunology therapeutic areas.
Market Dynamics
The global graves' disease market is propelled by several key drivers that collectively enhance market expansion and therapeutic advancement. The primary driver includes the rising global prevalence of autoimmune disorders, with environmental factors, genetic predisposition, and lifestyle changes contributing to increased incidence rates of graves' disease across diverse demographics. Enhanced diagnostic capabilities through sophisticated thyroid function testing, including TSI antibody detection, thyroid ultrasound, and radioactive iodine uptake scans, facilitate early disease identification and appropriate treatment initiation, thereby expanding the patient pool seeking therapeutic interventions.
Growing healthcare expenditure, improved insurance coverage for chronic autoimmune conditions, and increased patient awareness through digital health platforms and patient advocacy groups significantly boost market demand. However, the market faces notable restraints including high treatment costs associated with long-term medication regimens, potential side effects of antithyroid drugs leading to treatment discontinuation, and limited availability of specialized endocrinologists in emerging markets. Regulatory complexities surrounding radioactive iodine therapy, varying treatment guidelines across different regions, and challenges in achieving optimal treatment outcomes due to individual patient variability create additional market barriers.
Despite these constraints, substantial opportunities emerge through the development of novel therapeutic modalities including monoclonal antibodies, immunomodulatory agents, and personalized medicine approaches based on genetic profiling. The integration of telemedicine platforms for remote patient monitoring, artificial intelligence-driven diagnostic tools, and patient-centric care models present significant growth opportunities. Additionally, expanding healthcare infrastructure in emerging economies, increasing research investments in autoimmune disease therapeutics, and growing focus on combination therapy approaches offer promising avenues for market participants to capitalize on unmet medical needs and enhance treatment outcomes for graves' disease patients globally.
Key Features of the Study
- This report provides in-depth analysis of the global graves' disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global graves' disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Eli Lilly and Company, Merck & Co. Inc, GlaxoSmithKline plc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Sanofi, Bayer AG, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, AbbVie Inc, Roche Holding AG, and Johnson & Johnson
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global graves' disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global graves' disease market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Overt Graves' Disease
- Subclinical Graves' Disease
- Symptom Insights (Revenue, USD Bn, 2021 - 2033)
- Thyrotoxicosis
- Graves Orbitopathy (Ocular)
- Dermopathy (Pretibial Myxedema)
- Other Systemic Manifestations
- Diagnostic Method Insights (Revenue, USD Bn, 2021 - 2033)
- Clinical Evaluation
- Imaging
- Ultrasound
- Radioiodine Uptake Scan
- MRI/CT (for orbitopathy)
- Laboratory
- TSH
- Free T3/Free T4
- TSH Receptor Antibodies (TRAb)
- Treatment Modality Insights (Revenue, USD Bn, 2021 - 2033)
- Pharmacological
- Antithyroid Drugs
- Methimazole
- Propylthiouracil
- Carbimazole
- Beta Blockers
- Corticosteroids
- Immunosuppressants
- Radioactive Iodine Therapy
- Surgical
- Total Thyroidectomy
- Subtotal Thyroidectomy
- Adjunctive/Ocular
- Orbital Decompression
- Rituximab
- Teprotumumab
- Supportive/Other
- Lifestyle/Adjunctive Care
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Ambulatory Surgical Centers
- Home Care Settings
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- Novartis AG
- Eli Lilly and Company
- Merck & Co. Inc
- GlaxoSmithKline plc
- Bristol Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Sanofi
- Bayer AG
- Teva Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
- AbbVie Inc
- Roche Holding AG
- Johnson & Johnson
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Graves' Disease Market, By Disease Type
- Global Graves' Disease Market, By Symptom
- Global Graves' Disease Market, By Diagnostic Method
- Global Graves' Disease Market, By Treatment Modality
- Global Graves' Disease Market, By End User
- Global Graves' Disease Market, By Distribution Channel
- Global Graves' Disease Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Graves' Disease Market, By Disease Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Overt Graves' Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Subclinical Graves' Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Graves' Disease Market, By Symptom, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Thyrotoxicosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Graves Orbitopathy (Ocular)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dermopathy (Pretibial Myxedema)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Other Systemic Manifestations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Graves' Disease Market, By Diagnostic Method, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Clinical Evaluation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Imaging
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ultrasound
- Radioiodine Uptake Scan
- MRI/CT (for orbitopathy)
- Laboratory
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- TSH
- Free T3/Free T4
- TSH Receptor Antibodies (TRAb)
7. Global Graves' Disease Market, By Treatment Modality, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pharmacological
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Antithyroid Drugs
- Methimazole
- Propylthiouracil
- Carbimazole
- Beta Blockers
- Corticosteroids
- Immunosuppressants
- Radioactive Iodine Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Surgical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Total Thyroidectomy
- Subtotal Thyroidectomy
- Adjunctive/Ocular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Orbital Decompression
- Rituximab
- Teprotumumab
- Supportive/Other
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lifestyle/Adjunctive Care
8. Global Graves' Disease Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
9. Global Graves' Disease Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Graves' Disease Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Symptom, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diagnostic Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co. Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
